Q1 2020 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Q1 FY '20 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Jason D'souza. Thank you, and over to you, sir.
' -
Thank you, moderator. Welcome to Glenmark's Q1 Earnings Call. First, a review of operations for the quarter ended June 30, 2019. For the first quarter of FY '19, '20, Glenmark's consolidated revenue was at INR 23,228 million, recording an increase of 7.26%.
India business. Sales from the formulation business in India for the first quarter was at INR 7,522 million, recording growth of 13.41%. The India business continued to outperform the industry growth. As per IQVIA, Q1 FY '20, Glenmark's India business recorded growth of 12% compared to IPM growth of 10%. As per IQVIA MAT 2019, Glenmark's India formulation business is ranked 14th, with market share of 2.18%.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |